Natural Products as a Robust Source of New Drugs and Drug Leads: Past Successes and Present Day Issues

American Journal of Cardiology

Volumn 101, Issue 10 SUPPL., 2008, Pages

  Rishton, Gilbert M ^a  

^a CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ASTAXANTHIN; CARDIOTONIC AGENT; CEFALOTIN; CELECOXIB; CODEINE; DIGITALIS; DIGOXIGENIN; DIGOXIN; IBUPROFEN; MORPHINE; NALTREXONE; NAPROXEN; NATURAL PRODUCT; NEW DRUG; OPIATE; OXYCODONE; PARACETAMOL; PENICILLIN G; ROFECOXIB; SALICYLIC ACID; TRACE ELEMENT;

ARTICLE; BIOTECHNOLOGY; CHEMICAL ANALYSIS; CONGESTIVE HEART FAILURE; DRUG INDUSTRY; DRUG RESEARCH; DRUG STRUCTURE; ETHNOBOTANY; FOOD CHAIN; HEART ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; MEDICINAL PLANT; MOULD; PRIORITY JOURNAL; WILLOW;

BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG INDUSTRY; ETHNOBOTANY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 43049183607     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.007     Document Type: Article

References (41)

1. Mueller-Kuhrt L. Successful, but often unconventional: the continued and long-term contribution of natural products to healthcare. Expert Opinion on Drug Discovery 2 (2007) 305-311
2. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 70 (2007) 461-477
3. Peterson I., and Anderson E.A. Chemistry: the renaissance of natural products as drug candidates. Science 310 (2005) 451-453
4. Wilson R.M., and Danishefsky S.J. Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. J Org Chem 71 (2006) 8329-8351
5. Zhang L., and Demain A.L. Natural products and drug discovery. In: Zhang L., and Demain A.L. (Eds). Natural Products: Drug Discovery and Therapeutic Medicine (2005), Humana Press, Totowa, NJ 3-29
6. Sashidhara K.V., and Rosaiah J.N. Various dereplication strategies using LC-MS for rapid natural product lead identification and drug discovery. Natural Product Communications 2 (2007) 193-202
7. Smyth W.F., McClean S., Hack C.J., Ramachandran V.N., Doherty B., Joyce C., O'Donnell F., Smyth T.J., O'Kane E., and Brooks P. The characterization of synthetic and natural-product pharmaceuticals by electrospray ionisation-mass spectrometry (ESI-MS) and liquid chromatography (LC)-ESI-MS. Trends Analyt Chem 25 (2006) 572-582
8. Ramirez P., Santoyo S., Garcia-Risco M.R., Senorans F.J., Ibanez E., and Reglero G. Use of specially designed columns for antioxidants and antimicrobials enrichment by preparative supercritical fluid chromatography. J Chromatogr 1143 (2007) 234-242
9. Aronson J.K. An Account of the Foxglove and its Medical Uses1785-1985 (1985), Oxford University Press, Oxford
10. Smith S. Digoxin, a new digitalis glucoside. J Chem Soc (1930) 508-510
11. Fisch C. William Withering: an account of the foxglove and some of its medical uses 1785-1985. J Am Coll Cardiol 5 suppl A (1985) 1A-2A
12. Skou J.C. Overview: the sodium-potassium pump. Methods Enzymol 156 (1988) 1-25
13. Schmitz R.F. Wilhelm Serturner and the discovery of morphine. Pharm Hist 27 (1985) 61-74
14. Ignelzi R.J., and Atkinson J.H. Pain and its modulation. Part 2. Efferent mechanisms. Neurosurgery 6 (1980) 584-590
15. Bosch F., and Banos J.-E. Acetylsalicylic acid and its derivatives: history of discovery. AINE 2 (1998) 108-117
16. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231 (1971) 232-235
17. Mardini I.A., and FitzGerald G.A. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. Mol Interv 1 (2001) 30-38
18. Sanghi S., MacLaughlin E.J., Jewell C.W., Chaffer S., Naus P.J., Watson L.E., and Dostal D.E. Cyclooxygenase-2 inhibitors: a painful lesson. Cardiovasc Hematol Disord Drug Targets 6 (2006) 85-100
19. Burnier M. The safety of rofecoxib. Expert Opin Drug Saf 4 (2005) 491-499
20. Bennett J.W., and Chung K.-T. Alexander Fleming and the discovery of penicillin. Adv Appl Microbiol 49 (2001) 163-184
21. Ghuysen J.-M. Penicillin-binding proteins. Wall peptidoglycan assembly and resistance to penicillin: facts, doubts and hopes. Int J Antimicrob Agents 8 (1997) 45-60
22. Travis A.S. Anilines: historical background. In: Rappoport (Ed). Chemistry of Anilines (2007), John Wiley & Sons, Inc, Chichester, UK 1-73 Zvi
23. Gaudilliere J.-P. Better prepared than synthesized: Adolf Butenandt, Schering Ag and the transformation of sex steroids into drugs (1930-1946). Stud Hist Philos Biol Biomed Sci 36 (2005) 612-644
24. Fox S., Farr-Jones S., and Yund M.A. High throughput screening for drug discovery: continually transitioning into new technology. J Biomol Screen 4 (1999) 183-186
25. Grabowski H.G., and Wang Y.R. The quantity and quality of worldwide new drug introductions, 1982-2003. Health Aff (Millwood) 25 (2006) 452-460
26. Lipinski C., and Hopkins A. Navigating chemical space for biology and medicine. Nature 432 (2004) 855-861
27. Lipinski C., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23 (1997) 3-25
28. Rishton G.M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 8 (2002) 86-96
29. DeWitte R.S., and Robins R.H. A hierarchical screening methodology for physicochemical/ADME/Tox profiling. Expert Opin Drug Metab Toxicol 2 (2006) 805-817
30. Rishton G.M. Reactive compounds and in vitro false positives in HTS. Drug Discov Today 2 (1997) 382-384
31. McGovern S.L., Caselli E., Grigorieff N., and Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45 (2002) 1712-1722
32. Arai H., Beierle K., Fullenwider C., Kai Z., and Rishton G.M. Chemically conditioned extracts of ginger oil: leadlike "alkaloidal" compounds derived from natural extracts via reductive amination (2006) Abstracts of the 40th Western Regional Meeting of the American Chemical Society; January 22-25, Anaheim, California. Abstract WRM-351
33. Meyers S.P. Developments in world aquaculture, feed formulations, and role of carotenoids. Pure Appl Chem 66 (1994) 1069-1076
34. Nakano T., Tosa M., and Takeuchi M. Improvement of biochemical features in fish health by red yeast and synthetic astaxanthin. J Agric Food Chem 43 (1995) 1570-1573
35. Breivik H., Sanna L.I., and Aanesen B.A. The use of fatty acid diesters of astaxanthin for enhancing the growth of farmed fish. PCT Int Appl (2003) 10
36. Hussein G., Sankawa U., Goto H., Matsumoto K., and Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod 69 (2006) 443-449
37. Palozza P., and Krinsky N.I. Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch Biochem Biophys 297 (1992) 291-295
38. McNulty H.P., Byun J., Lockwood S.F., Jacob R.F., and Mason R.P. Differential effects of carotenoids on lipid peroxidation due to membrane interactions: x-ray diffraction analysis. Biochim Biophys Acta 1768 (2007) 167-174
39. Petri D., and Lundebye A.-K. Tissue distribution of astaxanthin in rats following exposure to graded levels in the feed. Comp Biochem Physiol C Toxicol Pharmacol 145C (2007) 202-209
40. Foss B.J., Nadolski G., and Lockwood S.F. Hydrophilic carotenoid amphiphiles: methods of synthesis and biological applications. Mini Rev Med Chem 6 (2006) 953-969
41. Lockwood S.F., O'Malley S., Watumull D.G., Hix L.M., Jackson H., and Nadolski G. Structural carotenoid analogs for the inhibition and amelioration of disease. PCT Int Appl (2004) 278 CODEN: PIXXD2 WO 2004011423 A2 20040205 CAN 140:164047 AN 2004:101126